<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04227457</url>
  </required_header>
  <id_info>
    <org_study_id>LACOG 0116</org_study_id>
    <nct_id>NCT04227457</nct_id>
  </id_info>
  <brief_title>Prospective Epidemiological Study of Metastatic Non Small Cell Lung Cancer (NSCLC) in Latin America - LATINO Lung</brief_title>
  <official_title>Prospective Epidemiological Study of Metastatic Non Small Cell Lung Cancer (NSCLC) in Latin America - LATINO Lung</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Latin American Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Latin American Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To describe the overall survival of advanced NSCLC in Latin America.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To describe demographic and socioeconomic characteristics of patients newly diagnosed
           with advanced NSCLC

        -  To describe diagnostic methods, pathological profile and disease stage at diagnosis of
           advanced NSCLC

        -  To describe the practice patterns of therapeutic agents for treatment of advanced NSCLC

        -  To describe treatment responses, progression and survival times.

        -  To describe reasons for treatment discontinuation

        -  To identify associations between patient demographics, socioeconomic, pathology,
           treatment sequences and overall survival;

        -  To define the patient experience of advanced NSCLC and identify unmet needs in their
           diagnose and treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2018</start_date>
  <completion_date type="Anticipated">November 12, 2021</completion_date>
  <primary_completion_date type="Actual">November 8, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Overall survival of advanced NSCLC in Latin America</measure>
    <time_frame>Annually, during 3 years</time_frame>
    <description>Time from randomization or initiation of treatment to patient death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of socioeconomic characteristics of patients newly diagnosed with advanced NSCLC</measure>
    <time_frame>Annually, during 3 years</time_frame>
    <description>Description of the socioeconomical characteristics of the Latin America population with newly advanced NSCLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of pathological profile of advanced NSCLC</measure>
    <time_frame>Annually, during 3 years</time_frame>
    <description>Analysis of histology and molecular markers of advanced NSCLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the practice patterns of therapeutic agents for treatment of advanced NSCLC</measure>
    <time_frame>Annually, during 3 years</time_frame>
    <description>Description of the practice patterns of therapeutic agents for treatment of advanced NSCLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the treatment responses</measure>
    <time_frame>Annually, during 3 years</time_frame>
    <description>Description of the treatment responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of Treatment discontinuation</measure>
    <time_frame>Annually, during 3 years</time_frame>
    <description>Description of the reasons for treatment discontinuation</description>
  </secondary_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Lung Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The LATINO Lung study will prospectively recruit a minimum of 700 and up to 800 patients
        with advanced NSCLC, including locally advanced disease not amenable to curative treatment
        or metastatic disease from sites in Argentina, Brazil, Chile, Colombia, and Mexico. Other
        countries may be invited to participate.

        Patients will be recruited during an initial study period of 3 months, or more to reach the
        study minimum sample size, and will be followed for 3 years.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged 18 years or older;

          2. Newly diagnosed Non-Small Cell Lung Cancer (NSCLC) during the period of the study
             (which includes 3 months prior to site activation by LACOG, although they can have
             received anti-cancer treatment during that time);

          3. Histologically or cytologically confirmed advanced NSCLC:

               1. Stage IIIB that progressed after curative therapy (chemoradiation and/or
                  surgery);

               2. Stage IV metastatic disease (de novo or distant relapse)

          4. Any NSCLC histological subtype and molecular mutation;

          5. Any Eastern Cooperative Oncology Group (ECOG) Performance Status (0 to 4) at
             diagnosis;

          6. Patients assigned by treating physician to any therapy (i.e. chemotherapy, targeted
             agents, immunotherapy) or palliative care;

          7. Access to patient medical chart for data collection;

          8. Willing and able to provide written informed consent and privacy authorization for the
             release of personal health information.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustavo Werutsky, MD</last_name>
    <role>Study Director</role>
    <affiliation>Latin American Cooperative Oncology Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Voelcker</last_name>
    <phone>51 3384 5334</phone>
    <phone_ext>55</phone_ext>
    <email>laura.voelcker@lacog.org.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raíra Maschmann</last_name>
    <phone>51 3384 5334</phone>
    <phone_ext>55</phone_ext>
    <email>raira.maschmann@lacog.org.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro Oncologico Riojano</name>
      <address>
        <city>La Rioja</city>
        <state>Rioja</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Diego Kaen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto De Oncologia De Rosario</name>
      <address>
        <city>Santa Fe</city>
        <state>Rosário</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luis Fein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Medico San Roque</name>
      <address>
        <city>Córdoba</city>
        <state>Tucumán</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juan Zarbá</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CLION</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fernando Oliveira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NOB</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eldsamira Mascarenhas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRIO</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceará</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eduardo Cronemberger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sírio- Libanês</name>
      <address>
        <city>Brasília</city>
        <state>Distrito Federal</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Igor Morbeck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICTr</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Adriano Silva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Câncer de Londrina</name>
      <address>
        <city>Londrina</city>
        <state>Paraná</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Clodoaldo Campos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Caridade de Carazinho</name>
      <address>
        <city>Carazinho</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patricia Pacheco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CPO</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gustavo Werutsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCPA</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juliano Coelho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Moinhos de Vento</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Helena de Andrade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Mãe de Deus</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ana Gelatti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Reichow</name>
      <address>
        <city>Blumenau</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sandro Reichow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CNT Itajaí</name>
      <address>
        <city>Itajaí</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giuliano Borges</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barretos</name>
      <address>
        <city>Barretos</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Josiane Dias</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>COI Américas</name>
      <address>
        <city>Rio De Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mauro Zukin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>INCA</name>
      <address>
        <city>Rio De Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luiz Henrique Araujo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AC Camargo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vladimir Lima</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IBCC</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Felipe Cruz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundación Arturo López Pérez</name>
      <address>
        <city>Providencia</city>
        <state>Santiago</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pamela Salman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica del Country</name>
      <address>
        <city>Chapinero</city>
        <state>Bogotá</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andres Cardona</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncomedica</name>
      <address>
        <city>Montería</city>
        <state>Córdoba</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jose Lobaton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe</name>
      <address>
        <city>Robledo</city>
        <state>Medellín</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alicia Quiroba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Médico Nacional Siglo XXI</name>
      <address>
        <city>Ciudad de mexico</city>
        <state>Not Aplicable</state>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Raúl Trejo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>INCan</name>
      <address>
        <city>Ciudad de mexico</city>
        <state>Not Aplicable</state>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Oscar Arrieta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://globocan.iarc.fr/Pages/fact_sheets_population.aspx</url>
    <description>World Health Organization. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012.</description>
  </link>
  <reference>
    <citation>Goss PE, Lee BL, Badovinac-Crnjevic T, Strasser-Weippl K, Chavarri-Guerra Y, St Louis J, Villarreal-Garza C, Unger-Saldaña K, Ferreyra M, Debiasi M, Liedke PE, Touya D, Werutsky G, Higgins M, Fan L, Vasconcelos C, Cazap E, Vallejos C, Mohar A, Knaul F, Arreola H, Batura R, Luciani S, Sullivan R, Finkelstein D, Simon S, Barrios C, Kightlinger R, Gelrud A, Bychkovsky V, Lopes G, Stefani S, Blaya M, Souza FH, Santos FS, Kaemmerer A, de Azambuja E, Zorilla AF, Murillo R, Jeronimo J, Tsu V, Carvalho A, Gil CF, Sternberg C, Dueñas-Gonzalez A, Sgroi D, Cuello M, Fresco R, Reis RM, Masera G, Gabús R, Ribeiro R, Knust R, Ismael G, Rosenblatt E, Roth B, Villa L, Solares AL, Leon MX, Torres-Vigil I, Covarrubias-Gomez A, Hernández A, Bertolino M, Schwartsmann G, Santillana S, Esteva F, Fein L, Mano M, Gomez H, Hurlbert M, Durstine A, Azenha G. Planning cancer control in Latin America and the Caribbean. Lancet Oncol. 2013 Apr;14(5):391-436. doi: 10.1016/S1470-2045(13)70048-2.</citation>
    <PMID>23628188</PMID>
  </reference>
  <reference>
    <citation>Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016 Nov 10;375(19):1823-1833. Epub 2016 Oct 8.</citation>
    <PMID>27718847</PMID>
  </reference>
  <reference>
    <citation>Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440. Erratum in: N Engl J Med. 2015 Oct 15;373(16):1582.</citation>
    <PMID>25470694</PMID>
  </reference>
  <reference>
    <citation>Scagliotti G, Kim T, Crino L, Liu G, Gridelli C. Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study. Annals of Oncology 27 (Supplement 6): vi552-vi587, 2016 doi:10.1093/annonc/mdw435.41</citation>
  </reference>
  <reference>
    <citation>Strasser-Weippl K, Chavarri-Guerra Y, Villarreal-Garza C, Bychkovsky BL, Debiasi M, Liedke PE, Soto-Perez-de-Celis E, Dizon D, Cazap E, de Lima Lopes G Jr, Touya D, Nunes JS, St Louis J, Vail C, Bukowski A, Ramos-Elias P, Unger-Saldaña K, Brandao DF, Ferreyra ME, Luciani S, Nogueira-Rodrigues A, de Carvalho Calabrich AF, Del Carmen MG, Rauh-Hain JA, Schmeler K, Sala R, Goss PE. Progress and remaining challenges for cancer control in Latin America and the Caribbean. Lancet Oncol. 2015 Oct;16(14):1405-38. doi: 10.1016/S1470-2045(15)00218-1. Review.</citation>
    <PMID>26522157</PMID>
  </reference>
  <reference>
    <citation>Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, Lu S, Cheng Y, Han B, Chen L, Huang C, Qin S, Zhu Y, Pan H, Liang H, Li E, Jiang G, How SH, Fernando MCL, Zhang Y, Xia F, Zuo Y. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015 Sep;26(9):1883-1889. doi: 10.1093/annonc/mdv270. Epub 2015 Jun 23.</citation>
    <PMID>26105600</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 11, 2018</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>January 10, 2020</last_update_submitted>
  <last_update_submitted_qc>January 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

